mRNA encoding PBGD for the treatment of AIP has been patented [154], and this strategy not only restores the expression of PBGD and its activity but also decreases the level of the neurotoxic metabolites (ALA and PBG). This evidence concerns the gene HMBS and autoimmune pancreatitis.